SCHEMBL10024820

SCHEMBL10024820

Cc1cc2ccccc2c(-c2c(CP)c(C)cc3ccccc23)c1CP

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.45
CYP2A6 P11509 3/20 0.45
HTR2A P28223 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 4/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.38
HIF1A Q16665 1/20 0.37
CYP1B1 Q16678 1/20 0.37
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
CCR1 P32246 1/20 0.35
CCR8 P51685 1/20 0.35
ALOX5 P09917 1/20 0.35
TYMP P19971 1/20 0.35
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12583209 0.80 CYP1A2 (0.45) CYP1A2CYP2A6HTR2AL3MBTL1ALDH1A1
SCHEMBL22288196 0.76 HTR2A (0.60) CYP1A2CYP2A6HTR2AL3MBTL1ALDH1A1
SCHEMBL14204853 0.75 CYP1A2 (0.48) CYP1A2CYP2A6ALDH1A1HSD17B10HPGD
SCHEMBL31001028 0.74 CYP1A2 (0.52) CYP1A2CYP2A6L3MBTL1ALDH1A1HSD17B10
SCHEMBL8743898 0.73 CYP1A2 (0.47) CYP1A2CYP2A6HTR2AL3MBTL1ALDH1A1
SCHEMBL17417162 0.72 TRPM4 (0.47) CYP1A2CYP2A6HTR2AL3MBTL1ALDH1A1
SCHEMBL5153021 0.71 CYP1A2 (0.48) CYP1A2CYP2A6HTR2AALDH1A1HSD17B10
SCHEMBL3262903 0.71 LMNA (0.52) CYP1A2CYP2A6ALDH1A1HSD17B10HPGD
SCHEMBL31277250 0.71 LMNA (0.52) CYP1A2CYP2A6ALDH1A1HSD17B10HPGD
SCHEMBL10565049 0.71 CYP1A2 (0.44) CYP1A2CYP2A6HTR2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180195003-A1 PROCESS FOR THE STABILISATION OF LIQUID CRYSTAL MEDIA MERCK PATENT GMBH (DE) 2018-07-12 US disclosed
US-9347002-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2016-05-24 US disclosed
US-9212311-B2 Liquid-crystal display MERCK PATENT GMBH (DE) 2015-12-15 US disclosed
US-9090823-B2 Liquid crystal display MERCK PATENT GMBH (DE) 2015-07-28 US disclosed
US-9005720-B2 Liquid-crystal display MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9005721-B2 Liquid-crystal display MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-8999459-B2 Liquid crystal display MERCK PATENT GMBH (DE) 2015-04-07 US disclosed
US-20140240653-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2014-08-28 US disclosed
US-8778466-B2 Liquid-crystal display MERCK PATENT GMBH (DE) 2014-07-15 US disclosed
US-20140152922-A1 LIQUID CRYSTAL DISPLAY AND METHOD OF MANUFACTURING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2014-06-05 US disclosed
US-20140022473-A1 Liquid-crystal display MERCK PATENT GMBH (DE) 2014-01-23 US disclosed
US-20130306910-A1 Liquid Crystal Display MERCK PATENT GMBH (DE) 2013-11-21 US disclosed
US-8585925-B2 Liquid-crystalline medium and liquid-crystal display MERCK PATENT GMBH (DE) 2013-11-19 US disclosed
US-20130183460-A1 LIQUID-CRYSTALLINE MEDIA MERCK PATENT GMBH (DE) 2013-07-18 US disclosed
US-20120162595-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-06-28 US disclosed
US-20120032112-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-02-09 US disclosed
US-20110255048-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2011-10-20 US disclosed
US-20100304049-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-12-02 US disclosed
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT (DE) 2010-10-28 US disclosed
US-20080090026-A1 Liquid-crystal display MERCK PATENT GMBH 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110255048-A1 LIQUID-CRYSTAL DISPLAY KLK3, BPHL, LPXN CYP1A2 4285/4885CYP2A6 3852/4885HTR2A 2323/4885
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY KLK3, BPHL, LPXN CYP1A2 3620/4885CYP2A6 3110/4885HTR2A 2514/4885
US-20080090026-A1 Liquid-crystal display KLK3, LPXN, BPHL CYP1A2 4291/4885CYP2A6 3639/4885HTR2A 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.